Displaying drugs 2001 - 2025 of 6001 in total
Progerinin
Investigational
Glenzocimab
Investigational
North-methanocarbathymidine
Investigational
Veligrotug
Veligrotug is under investigation in clinical trial NCT00791544 (Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma).
Investigational
Camoteskimab
Camoteskimab is under investigation in clinical trial NCT06436183 (A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis).
Investigational
MRx-4DP0004
MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Investigational
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
PF-06835919
PF-06835919 is under investigation in clinical trial NCT05463575 (Ketohexokinase Inhibition in NAFLD).
Investigational
Apc001PE
Investigational
Iclepertin
Iclepertin is under investigation in clinical trial NCT05211947 (A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study).
Investigational
Cendakimab
Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
Investigational
Iluzanebart
Investigational
Otlertuzumab
Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Investigational
VAD-044
VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.
Investigational
Zanzalintinib
Investigational
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
VK-0214
Investigational
BMN-046
Experimental
Withdrawn
BMN-055
Experimental
Withdrawn
Zorevunersen
Investigational
Porgaviximab
Investigational
Ponezumab
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Investigational
Bepranemab
Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.
Investigational
Mavodelpar
Investigational
VPO-227
Investigational
Matched Iupac: … -bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.0^{2,7}.0^ …
Displaying drugs 2001 - 2025 of 6001 in total